Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples